ADMA Biologics Inc (NASDAQ:ADMA) Receives $19.00 Average Price Target from Analysts

Posted by Brenda Bartman on May 15th, 2026

ADMA Biologics Inc (NASDAQ:ADMA – Get Free Report) has been given an average rating of “Hold” by the five brokerages that are presently covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $19.00.

A number of analysts have recently commented on ADMA shares. Mizuho cut their price target on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Zacks Research downgraded ADMA Biologics from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 27th. Wall Street Zen downgraded ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Finally, Canaccord Genuity Group lowered their target price on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th.

Read Our Latest Research Report on ADMA

ADMA Biologics Stock Performance

ADMA stock opened at $8.50 on Friday. The business’s 50-day moving average price is $11.36 and its two-hundred day moving average price is $15.23. The company has a current ratio of 6.95, a quick ratio of 3.93 and a debt-to-equity ratio of 0.51. The firm has a market cap of $1.97 billion, a PE ratio of 12.50 and a beta of 0.83. ADMA Biologics has a 1-year low of $7.21 and a 1-year high of $22.37.

ADMA Biologics (NASDAQ:ADMA – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, meeting analysts’ consensus estimates of $0.19. The company had revenue of $114.49 million for the quarter, compared to analyst estimates of $139.98 million. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The company’s quarterly revenue was down .3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.11 earnings per share. As a group, research analysts forecast that ADMA Biologics will post 0.84 earnings per share for the current year.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $15.63, for a total transaction of $157,800.48. Following the transaction, the chief operating officer owned 466,600 shares of the company’s stock, valued at $7,292,958. The trade was a 2.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Steve Elms purchased 7,000 shares of the stock in a transaction on Thursday, March 5th. The shares were acquired at an average cost of $15.67 per share, for a total transaction of $109,690.00. Following the transaction, the director owned 2,038,730 shares of the company’s stock, valued at approximately $31,946,899.10. The trade was a 0.34% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 3.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On ADMA Biologics

Institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp boosted its stake in shares of ADMA Biologics by 0.3% in the fourth quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company’s stock valued at $248,014,000 after buying an additional 35,614 shares during the period. Sachem Head Capital Management LP boosted its stake in shares of ADMA Biologics by 27.0% in the fourth quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock valued at $207,480,000 after buying an additional 2,415,000 shares during the period. Westfield Capital Management Co. LP boosted its stake in shares of ADMA Biologics by 36.9% in the fourth quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock valued at $127,551,000 after buying an additional 1,886,105 shares during the period. Capital Research Global Investors boosted its stake in shares of ADMA Biologics by 104.0% in the fourth quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock valued at $121,067,000 after buying an additional 3,383,559 shares during the period. Finally, Nuveen LLC boosted its stake in shares of ADMA Biologics by 3.5% in the fourth quarter. Nuveen LLC now owns 5,926,390 shares of the biotechnology company’s stock valued at $108,097,000 after buying an additional 202,245 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s stock.

About ADMA Biologics

(Get Free Report)

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.